Silencing hepatitis B virus prevent recurrence of liver cancer
June 23, 2010 by admin · Leave a Comment
(PHILADELPHIA) Previous studies have shown that antiviral treatment reduces the incidence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). But now, researchers from the Division of Gastroenterology and Hepatology at Thomas Jefferson University are reporting that the antiviral therapy also prevents recurrence of HCC and extends patients’ lives.
VARI findings could help diagnose and treat liver cancer
June 7, 2010 by admin · Leave a Comment
Contact: Joe Gavan
joe.gavan@vai.org
616-234-5390
Van Andel Research Institute Read more
New study confirms link between nonalcoholic steatohepatitis and liver cancer
May 24, 2010 by admin · Leave a Comment
Contact: Dawn Peters
medicalnews@wiley.com
781-388-8408
Wiley-Blackwell Read more
Androgen receptor may explain male dominance in liver cancer
May 18, 2010 by admin · Leave a Comment
Contact: Leslie Orr
Leslie_Orr@urmc.rochester.edu
585-275-5774
University of Rochester Medical Center
A University of Rochester study helps to explain why men get liver cancer more often than women and opens the door for a new treatment pathway, by showing a direct link between the androgen receptor, which is more active in men, and the hepatitis B virus as it relates to the deadly cancer.
Researchers identify new gene involved in the development of liver cancer
April 18, 2010 by admin · Leave a Comment
Contact: Sathya Achia Abraham
sbachia@vcu.edu
804-827-0890
Virginia Commonwealth University
RICHMOND, Va. (April 19, 2010) Virginia Commonwealth University researchers have identified a new tumor-promoting gene that may play a key role in the development of liver cancer. Levels of the gene’s expression are significantly higher in more than 90 percent of patients with the disease compared to their healthy counterparts.
Genetic signatures provide new direction in liver cancer
Contact: Isabelle Scali
media.easl2010@cohnwolfe.com
44-771-743-5103
European Association for the Study of the Liver Read more
US doctors sanction transplant criteria for liver cancer patients
March 4, 2010 by admin · Leave a Comment
Contact: Dawn Peters
medicalnews@wiley.com
781-388-8408
Wiley-Blackwell Read more
Cases of liver cancer reduced in a younger population vaccinated for HBV
September 16, 2009 by admin · Leave a Comment
A 20-year follow-up study revealed a dramatic drop in liver cancer cases among 6- to 19-year-olds who were vaccinated for the hepatitis B virus at birth, according to a study published online September 16 in the Journal of the National Cancer Institute.
SAMe is Effective in Preventing Formation of Primary Liver Cancer in Rats
July 30, 2009 by admin · Leave a Comment
A new study investigated the effectiveness of S-adenosylmethionine (SAMe) in the prevention and treatment of hepatocellular carcinoma (HCC) or primary liver cancer. SAMe, a widely available nutritional supplement, with little known side effects, was found to be effective in preventing the formation of HCC in rats. However, high enough levels of SAMe were not attainable to successfully treat established HCC. The findings are available in the August issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases.
A potential drug for liver carcinoma identified
May 24, 2009 by admin · Leave a Comment
Looking for efficient anti-tumor drugs is a hot research area. Chrysin (5,7-dihydroxy flavone), a natural widely-distributed flavonoid, has been reported to have many different biological activities such as anti-oxidant, anti-virus, antidiabetogenic activity and clear anxiolytic effect. However, Chrysin is limited in its clinical application because of its modest absorption in the intestine and rapid in vivo glycosylation. To improve the biological activity of chrysin, a number of its derivatives have been prepared for biological testing. 5-allyl-7-gen-difluoromethylenechrysin (ADFMChR) is one of them.
